Chris G Parsons

Summary

Affiliation: Merz Pharmaceuticals
Country: Germany

Publications

  1. ncbi Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance
    Wojciech Danysz
    Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt Main, Germany
    Neuropharmacology 48:360-71. 2005
  2. doi Memantine does not show intracellular block of the NMDA receptor channel
    Chris G Parsons
    Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D 60318, Frankfurt, Germany
    Eur J Pharmacol 587:99-103. 2008
  3. doi MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
    Christopher G Parsons
    Merz Pharmaceuticals, Eckenheimer Landstrasse 100, D 60318 Frankfurt, Germany Electronic address
    Neuropharmacology 92:158-69. 2015
  4. doi Patch clamp combined with voltage/concentration clamp to determine the kinetics and voltage dependency of N-methyl-D-aspartate (NMDA) receptor open channel blockers
    Chris G Parsons
    Pharmacology, Non Clinical Science, Merz Pharmaceuticals GmbH, Eckenheimer Landstraße 100, 60318, Frankfurt am Main, Germany
    Methods Mol Biol 1183:43-63. 2014
  5. pmc Pharmacodynamics of memantine: an update
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, 80804 Munich, Germany
    Curr Neuropharmacol 6:55-78. 2008
  6. pmc Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease
    Chris G Parsons
    In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318, Frankfurt, Germany
    Neurotox Res 24:358-69. 2013
  7. doi Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes
    Chris G Parsons
    In Vitro Pharmacology, Preclinical Research and Development, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D 60318, Frankfurt am Main 1, Germany
    J Neural Transm 115:1367-73. 2008
  8. ncbi Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker
    Chris G Parsons
    Head in Vitro Pharmacology, Preclinical Research and Development, Merz Pharmaceuticals GmbH, Germany
    Methods Mol Biol 403:15-36. 2007
  9. ncbi The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
    Wojciech Danysz
    Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
    Int J Geriatr Psychiatry 18:S23-32. 2003
  10. doi Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors
    Kate E Gilling
    In Vitro Pharmacology, Preclinical Research and Development, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D 60318 Frankfurt am Main 1, Germany
    Neuropharmacology 56:866-75. 2009

Collaborators

  • Wojciech Danysz
  • Andrzej Dekundy
  • G Rammes
  • Andreas Gravius
  • István Gyertyán
  • Ewa Kozela
  • Gary L Wenk
  • Anton Bespalov
  • Wolfgang Loscher
  • P Popik
  • B A Chizh
  • Jens Nagel
  • Martine Hofmann
  • Kate E Gilling
  • Kinga Szydlowska
  • Thomas Christoph
  • Simona Patierno
  • Ivan O Medvedev
  • Tadeusz Frankiewicz
  • Cheng Song
  • Kai Uwe Klein
  • Gunnar Flik
  • Carsten Tober
  • Sergio Greco
  • Ina M Wittko-Schneider
  • László Dézsi
  • Krisztina Sz Kordás
  • Katalin Sághy
  • Kata Bölcskei
  • Csilla Horváth
  • Mirko Hechenberger
  • Claudia Jatzke
  • Andrea Baude
  • Bozena Kaminska
  • Klaus Schiene
  • Werner Englberger
  • Marcello Tonini
  • Anthony Ho
  • K C Kent Lloyd
  • Catia Sternini
  • Wubanche Zellalem
  • Irina A Sukhotina
  • Natalia Y Sevostianova
  • Edwin E Zvartau
  • Kamal Aliev
  • Andrey A Malyshkin
  • Irina V Belozertseva
  • Ya Fang Liu
  • Yuntian Zhang

Detail Information

Publications22

  1. ncbi Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance
    Wojciech Danysz
    Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt Main, Germany
    Neuropharmacology 48:360-71. 2005
    ..The present data suggest that blockade of NMDA receptor/glycine(B) sites in the periphery may attenuate tolerance to the antinociceptive effects of morphine...
  2. doi Memantine does not show intracellular block of the NMDA receptor channel
    Chris G Parsons
    Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D 60318, Frankfurt, Germany
    Eur J Pharmacol 587:99-103. 2008
    ..In conclusion, intracellular block of the NMDA receptor, as reported for Mg2+, is not of significance for the therapeutic effects of memantine...
  3. doi MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
    Christopher G Parsons
    Merz Pharmaceuticals, Eckenheimer Landstrasse 100, D 60318 Frankfurt, Germany Electronic address
    Neuropharmacology 92:158-69. 2015
    ..Moreover, in vivo studies demonstrate the neuroprotective potential of MRZ-99030 after systemic and topical administration in animal models of Alzheimer's disease and glaucoma/AMD respectively...
  4. doi Patch clamp combined with voltage/concentration clamp to determine the kinetics and voltage dependency of N-methyl-D-aspartate (NMDA) receptor open channel blockers
    Chris G Parsons
    Pharmacology, Non Clinical Science, Merz Pharmaceuticals GmbH, Eckenheimer Landstraße 100, 60318, Frankfurt am Main, Germany
    Methods Mol Biol 1183:43-63. 2014
    ....
  5. pmc Pharmacodynamics of memantine: an update
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, 80804 Munich, Germany
    Curr Neuropharmacol 6:55-78. 2008
    ..In addition, there has been further confirmation of the MOA of memantine as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side effect profile of memantine...
  6. pmc Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease
    Chris G Parsons
    In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318, Frankfurt, Germany
    Neurotox Res 24:358-69. 2013
    ..Preclinical data have shown how these drugs act via two different, but interconnected, pathological pathways, and that their complementary activity may produce greater effects than either drug individually...
  7. doi Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes
    Chris G Parsons
    In Vitro Pharmacology, Preclinical Research and Development, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D 60318, Frankfurt am Main 1, Germany
    J Neural Transm 115:1367-73. 2008
    ..These results provide further support for the hypothesis that rapid relief of block via strong synaptic membrane depolarisation underlies the good therapeutic profile of memantine...
  8. ncbi Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker
    Chris G Parsons
    Head in Vitro Pharmacology, Preclinical Research and Development, Merz Pharmaceuticals GmbH, Germany
    Methods Mol Biol 403:15-36. 2007
    ....
  9. ncbi The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
    Wojciech Danysz
    Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
    Int J Geriatr Psychiatry 18:S23-32. 2003
    ..As such, if overactivation of NMDA receptors is present in AD, memantine would be expected to improve both symptoms (cognition) and to slow down disease progression because it takes over the physiological function of magnesium...
  10. doi Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors
    Kate E Gilling
    In Vitro Pharmacology, Preclinical Research and Development, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D 60318 Frankfurt am Main 1, Germany
    Neuropharmacology 56:866-75. 2009
    ....
  11. pmc Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections
    Wojciech Danysz
    Merz Pharmaceuticals GmbH, Eckenheimer Landstraße, Frankfurt am Main, Germany
    Br J Pharmacol 167:324-52. 2012
    ....
  12. ncbi Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse
    Chris G Parsons
    Merz Pharmaceuticals, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:699-723. 2007
    ....
  13. doi Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function
    Martine Hofmann
    Departments of In vivo Pharmacology, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
    Behav Pharmacol 23:790-801. 2012
    ..Therefore, the anxiolytic effect and the lack of side-effects of these compounds, as described in the literature, could not be confirmed in the present study...
  14. doi Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy - Comparison to MPEP
    Jens Nagel
    Merz Pharmaceuticals GmbH, Frankfurt Main, Germany
    Pharmacol Rep 67:624-30. 2015
    ..To verify relation between brain free levels, receptor occupancy in vivo and in vitro affinity at the target for mGluR5 negative allosteric modulator (NAM) MTEP...
  15. ncbi Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo
    Tadeusz Frankiewicz
    Department of Preclinical Research and Development, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt Main, Germany
    Neurotox Res 5:617-22. 2004
    ..3%). We conclude that although NMDA receptors do seem to be involved in chemically-induced ischaemic tolerance, semi-chronic pre-treatment with therapeutically-relevant doses of memantine does not block ischaemic tolerance...
  16. ncbi Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine
    Gary L Wenk
    Department Psychology and Neuroscience, Ohio State University, Ohio, USA
    Behav Pharmacol 17:411-24. 2006
    ....
  17. ncbi Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain
    Ivan O Medvedev
    Institute of Pharmacology, Pavlov Medical University, 6 8 Lev Tolstoy Street, 197089 St Petersburg, Russia
    Neuropharmacology 47:175-83. 2004
    ..Thus, studies on the prevention and management of chronic pain should focus on preemptive or long-term administration of NMDA receptor antagonists...
  18. ncbi Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo
    Kinga Szydlowska
    Laboratory of Transcription Regulation, The Nencki Institute of Experimental Biology, Pasteur 3 Street, 02 093 Warsaw, Poland
    Eur J Pharmacol 554:18-29. 2007
    ..EMQMCM was not protective at 5 mg/kg (given 2 h after occlusion) but at 10 mg/kg 50% of neuroprotection was observed. The present data support stronger neuroprotective potential of mGlu5 than mGlu1 antagonists...
  19. ncbi The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism
    Thomas Christoph
    Department of Pharmacology, Grünenthal GmbH Research Centre, Zieglerstrasse 6, 52078 Aachen, Germany
    Neuropharmacology 51:12-7. 2006
    ..Development of short-acting NMDA antagonists could represent a strategy for improving their tolerability...
  20. ncbi mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy
    Wolfgang Loscher
    Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Bunteweg 17, D 30559 Hannover, Germany
    Neuropharmacology 50:1006-15. 2006
    ..The present results do not support a significant anticonvulsant potential of group I mGlu receptor antagonists in rodent models of difficult-to-treat partial epilepsy...
  21. ncbi N-methyl-D-aspartate receptors mediate endogenous opioid release in enteric neurons after abdominal surgery
    Simona Patierno
    CURE Digestive Diseases Research Center, Digestive Diseases Division, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 90073, USA
    Gastroenterology 128:2009-19. 2005
    ..We tested the hypothesis that N-methyl-D-aspartate (NMDA) receptors mediate surgery-induced opioid release in enteric neurons...
  22. ncbi Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors
    Cheng Song
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 278:33364-9. 2003
    ....